<DOC>
	<DOCNO>NCT02207699</DOCNO>
	<brief_summary>The primary objective study determine effect benzonatate ( 200 mg 800 mg ) QT interval follow single dose oral administration time point post-dose .</brief_summary>
	<brief_title>Evaluation Effect Benzonatate QT Intervals Following Single Dose Administration Benzonatate Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Benzonatate</mesh_term>
	<criteria>Healthy male female subject age 18 55 year , inclusive . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12 lead ECG clinical laboratory test . Female subject nonchildbearing potential must meet least one follow criterion : 1 . Achieved postmenopausal status , define : cessation regular menses least 12 consecutive month alternative pathological physiological cause ; serum FSH level within laboratory 's reference range postmenopausal female ; 2 . Have undergone document hysterectomy and/or bilateral oophorectomy ; 3 . Have medically confirm ovarian failure . All female subject ( include female tubal ligation females NOT documented hysterectomy , bilateral oophorectomy and/or ovarian failure ) consider childbearing potential . Body mass index ( BMI ) 17.5 30.5 kg/m2 , inclusive , total body weight &gt; 50 kg ( 110 lb ) . Evidence personally sign date informed consent document indicate subject inform aspect study . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Significant ECG abnormality screening determine investigator . History risk factor QT prolongation torsades de pointes , congenital deafness family history sudden death . 12lead ECG demonstrate QTcF &gt; 450 msec QRS interval &gt; 110 msec Screening . Use medication dietary supplement capable induce inhibit hepatic enzyme metabolism transport ( e.g. , barbiturate , rifampin , carbamazepine , phenytoin , primidone , St. John 's Wort ) within 28 day first dose study medication . Consumption grapefruit grapefruit containing product within 7 day prior first dose study medication . Known history hypersensitivity , allergy , severe adverse drug reaction intolerance quinolone antibiotic . Known hypersensitivity benzonatate estertype local anesthetic ( ie , tetracaine , procaine ) . Subjects presence history dysphagia difficulty swallow pill . Subjects take concomitant anticonvulsant medication history seizure disorder . Subjects positive response question actual attempt suicidal behavior section CSSRS ( ColumbiaSuicide Severity Rating Scale ) . Subjects active suicidal ideation intent act within 6 month screen determine positive response question 4 5 suicidal ideation section CSSRS . Screening laboratory value consider clinically significant investigator . Screening supine blood pressure ≥140 mm Hg ( systolic ) ≥90 mm Hg ( diastolic ) , follow least 5 minute rest .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>